Biological Characteristics of Micrometastatic Cancer Cells in Bone Marrow (original) (raw)
References
Pantel K: Detection of minimal disease in patients with solid tumors. J Hematother 5: 359–367, 1996 Google Scholar
Schlimok G, Funke I, Holzmann B, Göttlinger HG, Schmidt G, Häuser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H, Riethmüller G: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti–17–1A monoclonal antibodies. Proc Natl Acad Sci USA 84: 8672–8676, 1987 Google Scholar
Pantel K, Schlimok G, Angstwurm M, Weckermann C, Schmaus W, Gath H, Passlick B, Izbicki J, Riethmüller G: Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3: 165–173, 1994 Google Scholar
Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC, McKinna A, Powles TJ, Coombes RC: Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 295: 1093–1096, 1987 Google Scholar
Salvadori B, Squicciarini P, Rovini D, Orefice S, Andreola S, Rilke F, Barletta L, Menard S, Colnaghi MI: Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer 26: 865–867, 1990 Google Scholar
Mathieu MC, Friedman S, Bosq J, Caillou B, Spielmann M, Travagli JP, Contesso G: Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat 15: 21–26, 1990 Google Scholar
Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D, Coombes RC: Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 27: 1552–1555, 1991 Google Scholar
Gogas H, Mansi JL, Bliss J, Coobmes RC: Can the presence of micrometastases in primary breast cancer predict outcome? Long-term (median 12.5 yrs) follow-up. Proc ASCO 16: 153a (abstract #537), 1997 Google Scholar
Kirk SJ, Cooper GG, Hoper M, Watt PC, Roy AD, Olding-Smee W: The prognostic significance of marrow micrometastases in women with early breast cancer. Eur J Surg Oncol 16: 481–485, 1990 Google Scholar
Harbeck N, Untch M, Pache L, Eiermann W: Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 69: 566–571, 1994 Google Scholar
Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayerr EF, Kaul S, Bastert G: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88: 1652–1664, 1996 Google Scholar
Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9: 1749–1756, 1991 Google Scholar
Singletary SE, Larry L, Trucker SL, Spitzer G: Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients. J Surg Oncol 47: 32–36, 1991 Google Scholar
Braun S, Schlimok G, Janni W, Hepp F, Kentenich CRM, Ehnle S, Gastroph S, Riethmüller G, Pantel K: Prediction of early metastatic relapse in patients with metastasis-free (M0) breast cancer by detection of occult cytokeratin-positive tumor cells in bone marrow. submitted, 1999
Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G: Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340: 685–689, 1992 Google Scholar
Juhl H, Stritzel M, Wroblewski A, Henne-Bruns D, Kremer B, Schmiegel W, Neumaier M, Wagener C, Schreiber HW, Kalthoff H: Immunocytological detection of micrometastatic cells: Comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 57: 330–335, 1994 Google Scholar
Jauch KW, Heiss MM, Gruetzner KU, Funke I, Pantel K, Babic R, Eissner HJ, Riethmüller G, Schildberg FW: Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 14: 1810–1817, 1996 Google Scholar
Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J, Riethmüller G: Micrometastatic tumor cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 27: 1461–1465, 1991 Google Scholar
Funke I, Fries S, Rolle M, Heiss MM, Untch M, Bohmert H, Schildberg FW, Jauch KW: Comparative analyses of bone marrow micrometastases in breast and gastric cancer. Int J Cancer 65: 755–761, 1996 Google Scholar
Thorban S, Roder JD, Nekarda H, Funk A, Siewert JR, Pantel K: Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst 88: 1222–1227, 1996 Google Scholar
Pantel K, Izbicki JR, Passlick B, Angstwurm M, Häussinger K, Thetter O, Riethmüller G: Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small cell lung cancer without overt metastases. Lancet 347: 649–653, 1996 Google Scholar
Cote RJ, Beattie EJ, Chaiwun B, Shi SR, Harvey J, Chen SC, Sherrod AC, Groshen S, Taylor CR: Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 222: 415–425, 1995 Google Scholar
Ohgami A, Mitsudomi T, Sugio K, Tsuda T, Oyama T, Nishida K, Osaki T, Yasumoto K: Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg 64: 363–367, 1997 Google Scholar
Oberneder R, Kriegmair M, Pantel K, Staudte S, Hofstetter A, Riethmüller G: Prognostic relevance of micrometastatic tumor cells in bone marrow of patients with genitourinary tract tumors. J Urol 151: 413A (abstract), 1994 Google Scholar
Riesenberg R, Oberneder R, Kriegmair M, Epp M, Bitzer U, Hofstetter A, Braun S, Riethmüller G, Pantel K: Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumor cells. Histochem 99: 61–66, 1993 Google Scholar
Mansi JL, Berger U, Wilson P, Shearer R, Coombes RC: Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques. J Urology 139: 545–548, 1988 Google Scholar
Braun S, Hepp F, Janni W, Blankenstein T, Pantel K: Occult tumor cells immunocytochemically identified in bone marrow of patients with apparently localized ovarian cancer predict early distant metastatic relapse. submitted, 1999
Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen M-J, Zedeler K: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337: 949–955, 1997 Google Scholar
Braun S, Pantel K: Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat 52: 201–216, 1998 Google Scholar
Pantel K, Schlimok G, Braun S, Kutter D, Schaller G, Funke I, Izbicki J, Riethmüller G: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85: 1419–1424, 1993 Google Scholar
Slamon JD, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Addition of Herceptin™ (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc ASCO 17: 98 (abstract 377), 1998 Google Scholar
Baselga J, Tripathy D, Mendelsohn J, Baughman BCC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton N: Phase II study of weekly intravenous recombinant humanized anti-p185Her2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744, 1996 Google Scholar
Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, The German Cancer Aid 17–1A Study Group: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 343: 1177–1183, 1994 Google Scholar
Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL: Association of tumor angiogenesis with bone marrow micrometastases in breast cancer. J Natl Cancer Inst 89: 1044–1049, 1997 Google Scholar
Maehara Y, Hasuda S, Abe T, Oki E, Kakeji Y, Ohno S, Sugimachi K: Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res 4: 2129–2134, 1998 Google Scholar
McCulloch P, Choy A, Martin L: Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346: 1334–1335, 1995 Google Scholar
Choy A, McCulloch P: Induction of tumor cell shedding into effluent venous blood during breast cancer surgery. Br J Cancer 73: 79–82, 1996 Google Scholar
Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T, Ohno S, Ichiyoshi Y, Sugimachi K: Cytokeratin-positive tumor cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br J Cancer 73: 83–87, 1996 Google Scholar
Braun S, Hepp F, Sommer HL, Pantel K: Tumor antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease. Int J Cancer (Pred Oncol) 84: 1–5, 1999 Google Scholar
Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmüller G: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51: 4712–4715, 1991 Google Scholar
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984 Google Scholar
Freeman JW, Busch RK, Gyorkey F, Gyorkey P, Ross BE, Busch H: Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase. Cancer Res 48: 1244–1251, 1988 Google Scholar
Fidler IJ, Radinsky R: Genetic control of cancer metastasis. J Natl Cancer Inst 82: 166–168, 1990 Google Scholar
Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336, 1991 Google Scholar
Price JE, Aukerman SL, Ananthaswamy N, McIntyre BW, Schackert G, Fidler IJ: Metastatic potential of cloned murine melanoma cells transfected with activated c-Haras. Cancer Res 49: 4274–4281, 1989 Google Scholar
Lane DP, Benchimol S: p53: oncogene or anti-oncogene? Genes Develop 4, 1990
Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675–679, 1990 Google Scholar
Hall PA, Ray A, Lemoine NR, Midley CA, Krausz T, Lane DP: p53 immununostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 338: 531, 1991 Google Scholar
Offner S, Schmaus W, Witter K, Barreton GB, Schlimok G, Passlick B, Riethmüller G, Pantel K: p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci USA, in press
Schlimok G, Riethmüller G: Detection, characterization and tumorigenicity of tumor cells in human bone marrow. Semin Cancer Biol 1: 207–215, 1990 Google Scholar
Slamon JD, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer. Science 244: 707–712, 1989 Google Scholar
Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S: Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 67: 625–629, 1993 Google Scholar
Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238–1243, 1988 Google Scholar
Tiwari RK, Borgen PI, Wong GY, Cordon CC, Osborne MP: HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12: 419–425, 1992 Google Scholar
Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1: 423–430, 1987 Google Scholar
Venter DJ, Tuzi NL, Kumar S, Gullick WJ: Overexpression of the c-erb-B-2 oncoprotein in human breast carcinomas: immunhistochemical assessment correlates with gene amplification. Lancet July 11: 69–72, 1987 Google Scholar
Taylor-Papadimitriou J: Oncogene signalling epithelial polarity and metastatic phenotype. The Lancet Conference, 1994. Brugge, Belgium, 1994: 7
Hoffman M: New clue found to oncogene's role in breast cancer. Science 256: 1129, 1992 Google Scholar
Lupu R, Colomer R, Kannan B, Lippman ME: Characterization of a growth factor that binds exclusively to the erbB2 receptor and induces cellular responses. Proc Natl Acad Sci USA 89: 2287–2291, 1992 Google Scholar
Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y: Isolation of the neu/HER-2 stimulatory ligand: a 44 kD glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205–216, 1992 Google Scholar
Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G, Zanker KS: Isolation of blood-borne epithelium derived c-erb-B2 oncoprotein-positive clustered cells from peripheral blood of breast cancer patients. Int J Cancer 76: 824–828, 1998 Google Scholar
Gatter KC, Alcock C, Heryet A, Mason DY: Clinical importance of analysing malignant tumours of uncertain origin with immunohistological techniques. Lancet I: 1302–1305, 1985 Google Scholar
Gallee MPW, van Vroonhoven CCJ, van der Korput HAGM, van der Kwast TH, ten Kate FJW, Romijn JC, Trapman J: Characterization of monoclonal antibodies raised against prostatic cell line PC-82. Prostate 9: 33–45, 1986 Google Scholar
Pallavicini MG, Cher ML, Bowers EE, Wessman M, Balouch M, Presti J, Carroll PR: Chromosomal aneusomies in prostate cancer marrow micrometastases (abstract). Proc Am Assoc Cancer Res 36: 69, 1995 Google Scholar
Riethmüller G, Johnson JP: Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr Opin Immunol 4: 647–655, 1992 Google Scholar
Hämmerling G, Maschek V, Sturmhöfel K, Momburg F: Regulation and functional role of MHC expression on tumors. In: Melchers F (ed) Prog Immunol Berlin: Springer, 1989: 1071–1078. Google Scholar
Hogg N, Landis RC: Adhesion molecules in cell interaction. Curr Opin Immunol 5: 383–390, 1993 Google Scholar
Springer TA: Adhesion receptors of the immune system. Nature 346: 425–434, 1990 Google Scholar
Johnson JP, Stade BG, Holzmann B, Schwäble W, Riethmüller G: De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 86: 641–644, 1989 Google Scholar
Passlick B, Izbicki JR, Simmel S, Kubuschok B, Karg O, Habekost M, Thetter O, Schweiberer L, Pantel K: Expression of major histocompatibility class I and class II antigens and intercellular adhesion moleule-1 on operable non-small cell lung carcinomas. Eur J Cancer 30: 376–381, 1994 Google Scholar
Pantel K, Angstwurm M, Kutter D, Braun S, Karg O, Izbicki JR, Werner U, Schlimok G, Riethmüller G: Down-regulation and neo-expression of cell surface antigens on individual micrometastatic carcinoma cells. In: Rabes H, Peters PE, Munk K (eds) Metastasis: Basic research and its clinical applications. Contrib. Oncol. Basel: Karger, 1992, Vol 44, 283–293 Google Scholar
Tomita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S: Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses. Int J Cancer 46: 1001–1006, 1990 Google Scholar
Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles F, Ben-Baruch N, Farbstein H, Lupu R: Neu differentiation factor (heregulin) induces expression of intercelular adhesion molecule 1: implications for mammary tumors. Cancer Res 53: 5251–5261, 1993 Google Scholar
Ménard S, Squicciarini P, Luini A, Sacchini V, Rovini D, Tagliabue F, Veronesi U, Colnaghi MI: Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with tumor prognostic features. Br J Cancer 69: 1126–1129, 1994 Google Scholar
Martignone S, Ménard S, Bufalino R, Cascinelli N, Pellegrini R, Tagliabue F, Andreola S, Rilke F, Colnaghi MI: Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst 85: 398–402, 1993 Google Scholar
Pardoll DM: Cancer vaccines. Immunol. Today 14: 310–316, 1993 Google Scholar
Nabel GJ, Felgner PL: Direct gene transfer for immunotherapy and immunization. In: Robinson C, Watson F (eds) Trends in biotechnology: Gene therapy — therapeutic strategies and commercial prospects. Cambridge: Bousfield, 1993: 211–214 Google Scholar
Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW: Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med. 1: 1035–1039, 1995 Google Scholar
Allgayer H, Heiss MM, Riesenberg R, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW: Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 57: 1394–1399, 1997 Google Scholar
Behrens J, Frixen U, Schipper J, Weidner M, Birchmeier W: Cell adhesion in invasion and metastasis. Semin Cell Biol 3: 169–178, 1992 Google Scholar
Hart IR, Goode NT, Wilson RE: Molecular aspects of the metastatic cascade. Biochem Biophys Acta 989: 65–84, 1989 Google Scholar
Schwarz MA, Owaribe K, Kartenbeck J, Franke WW: Desmosomes and hemidesmosomes: Constitutive molecular components. Annu Rev Cell Biol 6: 461–491, 1990 Google Scholar
Pfeifer M: Cancer, catenins, and cuticle pattern: a complex connection. Science 262: 667, 1993 Google Scholar
Göttlinger HG, Funke I, Johnson JP, Gokel JM, Riethmüller G: The epithelial cell surface antigen 17–1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38: 47–53, 1986 Google Scholar
Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, Pichlmayr R: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788–1794, 1998 Google Scholar
Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Hoechtlen-Vollmar W, Schlimok G, Weckermann D, Oberneder R, Fanning F, Riethmüller G: Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 87: 1162–1168, 1995 Google Scholar
Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson JP, Zahn R, Riethmüller G, Pantel K: Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 59: in press, 1999
Pantel K, Izbicki JR, Angstwurm M, Braun S, Passlick B, Karg O, Thetter O, Riethmüller G: Immunocytochemical detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 53: 1027–1031, 1993 Google Scholar
Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Höchtlen-Vollmar W, Schlimok G, Weckermann D, Oberneder R, Fanning E, Riethmüller G: Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 87: 1162–1168, 1995 Google Scholar
Delsite R, Djakiew D: Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell line. J Androl 17: 481–490, 1996 Google Scholar
Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM, Topalian SL: Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 57: 995–1002, 1997 Google Scholar
Franzen B, Lindner S, Alaiya AA, Erikson E, Uruy K, Hirano T, Okuzawa K, Auer G: Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins. Br J Cancer 74: 1632–1638, 1996 Google Scholar
Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E: Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 2: 1879–1885, 1996 Google Scholar
Mork C, van Deurs B, Petersen OW: Regulation of vimentin expression in cultured human mammary epithelial cells. Differentiation 43: 146–156, 1990 Google Scholar
Valles AM, Boyer B, Badet J, Tucker GC, Barritault D, Thiery JP: Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc Natl Acad Sci USA 87: 1124–1128, 1990 Google Scholar
Birchmeier C, Birchmeier W, Brand-Saberi B: Epithelial-mesenchymal transitions in cancer progression. Acta Anat 156: 217, 1996 Google Scholar
Hay ED: An overview of epitheho-mesenchymal transformation. Acta Anat 154: 8–20, 1996 Google Scholar
Osborn M, Weber K: Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest 48: 372–394, 1983 Google Scholar
Hülsken J, Behrens J, Birchmeier W: Tumor-suppressor gene products in cell contacts: the cadherin-APC-armadillo connection. Curr Opin Cell Biol 6: 711–716, 1994 Google Scholar
De Plaen F, Arden K, Traversari C, Gaforio JJ, Szikora J-P, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Brasseur F, Chomez P, De Backer O, Cavenee W, Boon T: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40: 360–369, 1994 Google Scholar
Damjanovich L, Albelda SM, Mette SA, Buck CA: Distribution of integrin cell adhesion receptors in normal and malignant lung tissue. Am J Respir Cell Mol Biol 6: 197–206, 1992 Google Scholar
Korhonen M, Laitinen L, Ylänne J, Koukoulis GK, Quaranta V, Juusela H, Gould VE, Virtanen I: Integrin distributions in renal cell carcinomas of various grades of malignancy. Am J Pathol 141: 1161–1171, 1992 Google Scholar
Kovarik J, Lauerová L, Rejthar A, Bártek J: Keratin typing in screening bone marrows for carcinoma cells. Cytotechnology S78: 79, 1989 Google Scholar
Witkowski CM, Rabinovitz I, Nagle RB, Affinio K-S, Cress AE: Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 119: 637–644, 1993 Google Scholar
Gong J, Wang D, Sun L, Zborowska E, Willson JK, Brattain MG: Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 8: 83–90, 1997 Google Scholar
O'Brien V, Frisch SM, Juliano RL: Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation. Exp Cell Res 224: 208–213, 1996 Google Scholar
Van der Velde-Zimmermann D, Verdaasdonk MA, Rademakers LH, De Weger RA, Van den Tweel JG, Joling P: Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res 230: 111–120, 1997 Google Scholar
Boudreau N, Sympson CJ, Werb Z, Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267: 891–893, 1995 Google Scholar
Albelda S: Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Laboratory Investigation 68: 4–17, 1993 Google Scholar
Grano M, Zigrino P, Colucci S, Zambonin G, Trusolino L, Serra M, Baldini N, Teti A, Marchisio PC, Zallone AZ: Adhesion properties and integrin expression of cultured human osteoclast-like cells. Exp Cell Res 212: 209–218, 1994 Google Scholar
Liapis H, Flath A, Kitazawa S: Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mo Pathol 5: 127–135, 1996 Google Scholar
Pellegrini R, Martignone S, Ménard S, Colnaghi MI: Laminin receptor expression and function in small-cell lung carcinoma. Int J of Cancer: Suppl 8: 116–120, 1994 Google Scholar
Tuszynski GP, Wang TN, Berger D: Adhesive proteins and the hematogenous spread of cancer. Acta Haematol 97: 29–39, 1997 Google Scholar
Ardini F, Tagliabue E, Magnifico A, Buto S, Castronovo V, Colnaghi MI, Menard S: Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin. J Biol Chem 272: 2342–2345, 1997 Google Scholar
Sers C, Riethmüller G, Johnson JP: MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res 54: 5689–5694, 1994 Google Scholar
Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow PM, Riethmüller G, Johnson JP: Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47: 841–845, 1987 Google Scholar
Xie K, Huang S, Dong Z, Juang SH, Wang Y, Fidler IJ: Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 89: 421–427, 1997 Google Scholar
Gunthert U: CD44 in malignant disorders. Curr Top Microbiol Immunol 213: 271–285, 1996 Google Scholar
Noordzij MA, Van Steenbrugge GJ, Verkaik NS, Schröder FH, Van der Kwast TH: The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostectomy. Clin Cancer Res 3: 805–815, 1997 Google Scholar
Soukka KT, Salmi M, Joensuu H, Häkkinen L, Sointu P, Koulu L, Kalimo K, Kiemi P, Grénman R, Jalkanen S: Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 57: 2281–2289, 1997 Google Scholar
Kogerman P, Sy M-S, Culp LA: Overexpressed human CD44s promotes lung colonization during micrometastasis of murine fibrosarcoma cells: facilitated retention in the lung vasculature. Proc Natl Acad Sci USA 94: 13233–13238, 1997 Google Scholar
Pantel K, Enzmann T, Köllermann J, Caprano J, Riethmüller G, Köllermann MW: Immunocytochmical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 71: 521–525, 1997 Google Scholar
Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 12: 1497–1515, 1994 Google Scholar
Braun S, Hepp F, Janni W, Sommer HL, Pantel K: Reduction of micrometastatic tumor load by monoclonal antibody therapy: influence of tumor antigen heterogeneity. Ann Oncol 9: 129 (abstract 621), 1998 Google Scholar
Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmüller G: Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 31A: 1799–1803, 1995 Google Scholar
Scholz D, Lubeck M, Loibner H: Biological activity in the human system of isotype variants of oligosaccharide Y-specific murine monoclonal antibodies. Cancer Immunol Immunother 33: 153–157, 1991 Google Scholar
Hempel D, Müller P, Oruzio D, Ehnle S, Schlimok G: Adoptive immunotherapy with monoclonal antibody 17–1A to reduce minimal residual disease in breast cancer patients after high-dose chemotherapy. Blood 90Suppl 1: 379B, abstract 4454, 1997 Google Scholar
Hohaus S, Funk L, Brehm M, Abdallah A, Murea S, Kaul S, Haas R: Persistence of isolated tumor cells in patients with breast cancer after sequential high-dose therapy with peripheral blood stem cell transplantation. Blood 88Suppl 10: 128A, abstract 501, 1996 Google Scholar
Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50: 8145–8195, 1990 Google Scholar
Scott AM, Welt S: Antibody-based immunological therapies. Curr Opin Immunol 9: 717–722, 1997 Google Scholar